Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients

Biochemical and Biophysical Research Communications

Volumn 313, Issue 4, 2004, Pages 1079-1085

  Mochida, Satoshi ^a   Hashimoto, Michie ^b   Matsui, Atsushi ^a   Naito, Masashi ^a   Inao, Mie ^a   Nagoshi, Sumiko ^a   Nagano, Makoto ^c   Egashira, Tohru ^c   Mishiro, Shunji ^a,b   Fujiwara, Kenji ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Shinagawa ku   (Japan)

^c BML   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA FRAGMENT; OSTEOPONTIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DNA DETERMINATION; DNA SEQUENCE; EVALUATION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEPATITIS C; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OBSERVATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SAMPLE SIZE; SYNDROME DELINEATION;

HEPATITIS C VIRUS;

EID: 9144242442     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.045     Document Type: Article

References (27)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium, J. Viral Hepat. 6 (1999) 35-47.
2. Barrera J.M., Bruguera M., Ercilla M.G., Gil C., Celis R., Gil M.P., del Valle Onorato M., Rodes J., Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 21:1995;639-644.
3. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., Lettieri G., Pierri P., Chionne P., Ciccaglione A.R., Sagliocca L. Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 28:1998;939-944.
4. Tanaka E., Kiyosawa K. Natural history of acute hepatitis C. J. Gastroenterol. Hepatol. 15:2000;E97-E104.
5. Cerny A., Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology. 30:1999;595-601.
6. Tong M.J., el-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1995;1463-1466.
7. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S., Nishiguchi S., Kuroki T., Imazeki F., Yokosuka O., Kinoyama S., Yamada G., Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann. Intern. Med. 131:1999;174-181.
8. Naito M., Hayashi N., Hagiwara H., Hiramatsu N., Kasahara A., Fusamoto H., Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology. 19:1994;871-875.
9. Persico M., Persico E., Suozzo R., Conte S., De Seta M., Coppola L., Palmentieri B., Sasso F.C., Torella R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 118:2000;760-764.
10. Jamal M.M., Soni A., Quinn P.G., Wheeler D.E., Arora S., Johnston D.E. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology. 30:1999;1307-1311.
11. Uede T., Katagiri Y., Iizuka J., Murakami M. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein? Microbiol. Immunol. 41:1997;641-648.
12. Kawashima R., Mochida S., Matsui A., YouLuTuZ Y., Ishikawa K., Toshima K., Yamanobe F., Inao M., Ikeda H., Ohno A., Nagoshi S., Uede T., Fujiwara K. Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem. Biophys. Res. Commun. 256:1999;527-531.
13. Wang Y., Mochida S., Kawashima R., Inao M., Matsui A., YouLuTuZ Y., Nagoshi S., Uede T., Fujiwara K. Increased expression of osteopontin in activated Kupffer cells and hepatic macrophages during macrophage migration in Propionibacterium acnes-treated rat liver. J. Gastroenterol. 35:2000;696-701.
14. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 287:2000;860-864.
15. Patarca R., Saavedra R.A., Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13:1993;225-246.
16. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y.et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J. Gen. Virol. 73:1992;673-679.
17. De Arruda M., Lyamichev V.I., Eis P.S., Iszczyszyn W., Kwiatkowski R.W., Law S.M., Olson M.C., Rasmussen E.B. Invader technology for DNA and RNA analysis: principles and applications. Expert Rev. Mol. Diagn. 2:2002;487-496.
18. Yamamoto S., Hijiya N., Setoguchi M., Matsuura K., Ishida T., Higuchi Y., Akizuki S. Structure of the osteopontin gene and its promoter. Ann. N. Y. Acad. Sci. 760:1995;44-58.
19. Nagano M., Yamashita S., Hirano K., Ito M., Maruyama T., Ishihara M., Sagehashi Y., Oka T., Kujiraoka T., Hattori H., Nakajima N., Egashira T., Kondo M., Sakai N., Matsuzawa Y. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay. J. Lipid Res. 43:2002;1011-1018.
20. Devlin B., Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics. 29(2):1995;311-322.
21. Miyazaki Y., Setoguchi M., Yoshida S., Higuchi Y., Akizuki S., Yamamoto S. The mouse osteopontin gene: expression in monocytic lineages and complete nucleotide sequence. J. Biol. Chem. 265:1990;14432-14438.
22. Haga H., Yamada R., Ohnishi Y., Nakamura Y., Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J. Hum. Genet. 47:2002;605-610.
23. Seeff L.B. Natural History of Chronic Hepatitis C. Hepatology. 36:2002;S35-S46.
24. Puoti C., Magrini A., Stati T., Rigato P., Montagnese F., Rossi P., Aldegheri L., Resta S. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 26:1997;1308-1393.
25. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 136:2003;125-129.
26. Forton A.C., Petri M.A., Goldman D., Sullivan K.E. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum. Mutat. 19:2002;459.
27. Yee L.J., Tang J., Herrera J., Kaslow R.A., Van Leeuwen D.J. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun. 1:2000;386-390.